MannKind to Present at the Jefferies 2011 Global Healthcare Conference

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 4:00 PM (ET) in New York.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.



CONTACT:

MannKind Corporation
Matthew J. Pfeffer, 661-775-5300
Corporate Vice President and
Chief Financial Officer
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance  Research  Diabetes  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.